Atrogin-1 promotes muscle homeostasis by regulating levels of endoplasmic reticulum chaperone BiP

Avnika A. Ruparelia, …, Ralf B. Schittenhelm, Peter D. Currie


Graphical abstract

Find the latest version:
https://jci.me/167578/pdf
Atrogin-1 promotes muscle homeostasis by regulating levels of endoplasmic reticulum chaperone BiP

Avnika A. Ruparelia,1,2,3 Margo Montandon,1 Jo Merriner,1 Cheng Huang,4 Siew Fen Lisa Wong,1 Carmen Sonntag,1 Justin P. Hardee,3 Gordon S. Lynch,1 Lee B. Miles,1 Ashley Siegel,1 Thomas E. Hall,5 Ralf B. Schittenhelm,4 and Peter D. Currie1,6

1Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia. 2Department of Anatomy and Physiology, School of Biomedical Sciences, Faculty of Medicine Dentistry and Health Sciences, and 3Centre for Muscle Research, Department of Anatomy and Physiology, University of Melbourne, Melbourne, Victoria, Australia. 4Monash Proteomics and Metabolomics Facility, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia. 5Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia. 6EMBL Australia, Victorian Node, Monash University, Clayton, Victoria, Australia.

Introduction

Skeletal muscle wasting results from numerous pathological conditions affecting both the musculoskeletal and nervous systems. A unifying feature of these pathologies is the upregulation of members of the E3 ubiquitin ligase family, resulting in increased proteolytic degradation of target proteins. Despite the critical role of E3 ubiquitin ligases in regulating muscle mass, the specific proteins they target for degradation and the mechanisms by which they regulate skeletal muscle homeostasis remain ill-defined. Here, using zebrafish loss-of-function models combined with in vivo cell biology and proteomic approaches, we reveal a role of atrogin-1 in regulating the levels of the endoplasmic reticulum chaperone BiP. Loss of atrogin-1 resulted in an accumulation of BiP, leading to impaired mitochondrial dynamics and a subsequent loss in muscle fiber integrity. We further implicated a disruption in atrogin-1-mediated BiP regulation in the pathogenesis of Duchenne muscular dystrophy. We revealed that BiP was not only upregulated in Duchenne muscular dystrophy, but its inhibition using pharmacological strategies, or by upregulating atrogin-1, significantly ameliorated pathology in a zebrafish model of Duchenne muscular dystrophy. Collectively, our data implicate atrogin-1 and BiP in the pathogenesis of Duchenne muscular dystrophy and highlight atrogin-1’s essential role in maintaining muscle homeostasis.
Given such a central role for atrogin-1 in regulating atrophy, and muscle homeostasis, a key focus over the past few years has been to identify its cellular targets. In line with this, binding studies and in vitro ubiquitin ligase assays have revealed multiple substrates of atrogin-1, including the myogenic regulatory factor MyoD (13); the eukaryotic translation initiation factor 3 subunit f (eIF3-f) (14); sarcomeric proteins myosin, vimentin, and desmin (15); and calcineurin (7), although most remain to be validated in vivo. In addition to this, mass spectrometry analyses comparing protein turnover rates between atrogin-1–KO and control cardiomyocytes identified the ESCRT-III protein CHMP2B as a target of atrogin-1 (12). Whether similar proteins are targeted in skeletal muscle remains unknown. There is, therefore, a need to identify the cellular targets of atrogin-1 in skeletal muscle and mechanistically dissect how atrogin-1 regulates skeletal muscle mass and homeostasis.

In the present study, we used the in vivo cell biology approaches afforded by the zebrafish model coupled with systems proteomics to examine the mechanism by which atrogin-1 regulates skeletal muscle mass during homeostasis and disease. We reveal that a loss in atrogin-1 resulted in an accumulation of the endoplasmic reticulum (ER) chaperone binding immunoglobulin protein (BiP), which leads to mitochondrial impairment and a subsequent loss in muscle fiber integrity, highlighting a mechanism by which atrogin-1 maintains muscle homeostasis. We further implicated atrogin-1–mediated BiP regulation in the pathogenesis of Duchenne muscular dystrophy (DMD) using a zebrafish model of the disease, thereby suggesting alternative avenues for therapeutic intervention in this and other muscle wasting disorders.

Results

Loss of atrogin-1 results in contraction-dependent fiber failure. To determine the role of atrogin-1 in skeletal muscle, we used CRISPR/Cas9 genome editing to generate an atrogin-1 mutant (atrogin-1

Allele therapy of Duchenne muscular dystrophy (DMD) using a zebrafish model of the disease, thereby suggesting alternative avenues for therapeutic intervention in this and other muscle wasting disorders.
**Figure 1. Atrogin-1 deficiency results in contraction-dependent muscle fiber detachment.** Schematic of wild-type *atrogin-1* (*atrogin-1<sup>+/+</sup>*) and mutant *atrogin-1* (*atrogin-1<sup>–/–</sup>*) protein structure and mRNA sequence, with the mutant predicted to incorporate a premature stop in exon 1. The mutant was generated using CRISPR/Cas9 genome editing, which resulted in a 34 bp insertion (red). Numbers in the protein box are amino acids, and numbers in the mRNA box are base pairs. (B) qRT-PCR analysis showing significant reduction in *atrogin-1* levels in *atrogin-1<sup>–/–</sup>* mutants compared with *atrogin-1<sup>+/+</sup>* wild-type larvae. Error bars represent mean ± SEM for 3 replicate experiments, with each experiment comprising a pooled sample of at least 5 fish. *P* < 0.05 determined using a 1-way ANOVA with Tukey’s multiple correction post hoc test. Muscle fibers span the entire length of the somite in the 3 dpf *atrogin-1<sup>+/+</sup>* (C), *atrogin-1* heterozygous (*atrogin-1<sup>+</sup>–<sup>–</sup>*) (D), and *atrogin-1<sup>–/–</sup>* mutant (E) larvae, as seen by F-Actin labeling. (F) Quantification of the muscle phenotype, with *atrogin-1<sup>+/+</sup>*, *atrogin-1<sup>+</sup>–<sup>–</sup>*, and *atrogin-1<sup>–/–</sup>* displaying indistinguishable muscle structure, as determined using a χ² test. Incubation of 3 dpf *atrogin-1<sup>+</sup>–<sup>–</sup>*, (H) and *atrogin-1<sup>–/–</sup>* (I) in methyl cellulose results in muscle fiber detachment, which is not evident in *atrogin-1<sup>+/+</sup>* larvae (G). (J) Percentage of affected *atrogin-1<sup>+/+</sup>*, *atrogin-1<sup>+</sup>–<sup>–</sup>*, and *atrogin-1<sup>–/–</sup>* larvae, with the latter 2 genotypes having a significant increase in the proportion of fish displaying the muscle fiber detachment, as determined using a χ² test. At 6 dpf, *atrogin-1<sup>+</sup>–<sup>–</sup>*, (L) and *atrogin-1<sup>–/–</sup>* (M) display sporadic muscle fiber detachment but not in *atrogin-1<sup>+/+</sup>* larvae (K). (N) Percentage of affected *atrogin-1<sup>+/+</sup>*, *atrogin-1<sup>+</sup>–<sup>–</sup>*, and *atrogin-1<sup>–/–</sup>* larvae, with the latter 2 genotypes having a significant increase in the proportion of fish displaying the muscle fiber detachment, as determined using a χ² test. Methyl cellulose incubation of 6 dpf *atrogin-1<sup>+</sup>–<sup>–</sup>*, (P) and
atrogin-1+/– (Q) results in muscle fiber detachment, which is not evident in atrogin-1–/– larvae (O). (R) Percentage of affected atrogin-1+/–, atrogin-1–/–, and atrogin-1–/– larvae, with the latter 2 genotypes having a significant increase in the proportion of fish displaying the muscle fiber detachment, as determined using a χ^2 test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. All experiments were performed in triplicate, with the total number of fish examined in each replicate documented in Supplemental Table 2.

normal sarcolemma, selectively accumulates in cells in which the sarcolemma lacks integrity. Using this technique, we revealed that while muscle fibers in atrogin-1–/– larvae had no Evans blue dye uptake (Figure 2, G–I), consistent with the presence of intact sarcolemma, muscle cells in atrogin-1+/– mutants displayed an accumulation of dye (Figure 2, J–L), confirming an impairment in membrane integrity. Finally, to determine if the retracted muscle cells seen in the atrogin-1–/– mutant undergo apoptosis, we performed a TUNEL assay in methyl cellulose–treated, 6 dpf atrogin-1–/– and atrogin-1+/– mutants. In line with the normal muscle structure observed in atrogin-1+/+ wild-type larvae, we observed no apparent TUNEL labeling (Figure 2, M–O). In contrast, atrogin-1–/– mutants displayed increased numbers of TUNEL+ nuclei, which coincided with areas of muscle detachment (Figure 2, P–R). Collectively, these results highlight that loss of atrogin-1 results in a loss in membrane integrity and increased apoptosis, consistent with the phenotypes presented in atrogin-1–deficient cardiomyocytes.

Untargeted proteomics identified a role of atrogin-1 in regulating BiP levels. Having characterized the atrogin-1 mutant phenotype, we wanted to examine the mechanisms by which loss of atrogin-1 results in fiber detachment. Given the striking similarity in phenotypes between the zebrafish atrogin-1–KO animals and the atrogin-1–KO cardiomyocytes, we hypothesized that the same protein(s) may be dysregulated in both systems following the absence of atrogin-1, resulting in the pathology observed. To identify proteins differentially regulated in the zebrafish mutant, we performed mass spectrometry on protein lysates obtained from 6 dpf atrogin-1+/+ and atrogin-1–/– larvae. Using this strategy, we identified a total of 4,242 distinct proteins across the 6 samples (Supporting Data Values file). Of these, 162 proteins were differentially expressed in the atrogin-1–/– mutant larvae compared with atrogin-1+/+ larvae (Figure 3A), of which, 69 were upregulated and 93 downregulated (Supporting Data Values file). Given that a loss in atrogin-1 is expected to result in an accumulation of its targets — as they are no longer targeted for degradation — we focused on proteins that were upregulated in the mutant. A comparison of the 69 proteins upregulated in the atrogin-1–/– mutant with those shown to also have increased expression (56 proteins) or reduced turnover (137 proteins) in the atrogin-1–KO cardiomyocytes (12) revealed an overlap of 7 proteins (Table 1). Of these 7 proteins, the most upregulated was BiP (also known as GRP-78 or heat shock 70 kDa protein 5 [HSPA5]), a member of the HSP70 family of proteins localized primarily to the ER, where it regulates multiple processes, including activation of the unfolded protein response (UPR) following accumulation of unfolded or misfolded proteins, protein transport, cell survival and apoptosis, calcium homeostasis, and ER-mitochondrial calcium crosstalk, which subsequently regulates mitochondrial function (16, 17) (reviewed in ref. 18). Importantly, prolonged ER stress and chronic upregulation of BiP results in apoptosis, which is a characteristic feature of the atrogin-1 mutant, and atrogin-1–deficient cardiomyocytes (12). BiP accumulation is therefore a prime candidate that could explain the manifestation of atrogin-1 mutant phenotype, and as such all subsequent analyses were focused on defining BiP’s role in maintaining muscle homeostasis.

To confirm that BiP is indeed upregulated in the atrogin-1 mutant, we performed Western blotting for BiP on whole cell protein lysate. In line with our untargeted proteomics data, atrogin-1–/– larvae displayed a significant increase in BiP compared with atrogin-1+/+ larvae (Figure 3, B and C). One possible explanation for the increased levels of BiP is increased transcription. To test this possibility, we performed qRT-PCR for the UPR genes bip, chop, atf6, and atf4. Our results indicate no difference in the expression of these genes between atrogin-1+/+ wild-type and atrogin-1–/– larvae (Supplemental Figure 2A). Therefore, the increased levels of BiP seen in the mutant were not due to increased transcription. We next wished to determine if BiP is a direct target of atrogin-1, which could explain the increased levels of BiP in the atrogin-1 mutant. To this end, we conducted coimmunoprecipitation experiments in HEK293T cells by cotransfecting with plasmids encoding GFP (control), Myc-tagged zebrafish atrogin-1, and/or HA-tagged zebrafish BiP and, subsequently, performing a pull-down assay using anti-Myc–coated beads. While Myc-atrogin-1 was enriched in the Myc-atrogin-1 and in the Myc-atrogin-1– and BiP-HA–transfected cells, indicating successful pull down, no HA-tagged BiP was detected in any of the immunoprecipitated lysates (Supplemental Figure 2B). These results indicate that BiP is not a direct target of atrogin-1. Our results suggest that BiP levels are indirectly regulated...
by atrogin-1 and the increased abundance in the atrogin-1 mutant is likely a secondary consequence of atrogin-1 deficiency.

Accumulation of BiP results in muscle detachment following the loss of atrogin-1. Having confirmed that BiP is upregulated in atrogin-1–deficient larvae, we next wanted to determine if its increased level was responsible
for the loss in muscle integrity observed in the atrogin-1–/– mutant. To address this, we treated 3 dpf larvae with the well-characterized ER stress inducers tunicamycin (Tm) or thapsigargin (Tg) for 3 days, which not only induced *bip* expression, but also expression of the UPR genes *chop*, *atf6*, and *atf4* (Supplemental Figure 2C). Examination of muscle structure in Tm- or Tg-treated fish revealed a significant increase in the proportion of muscle fibers displaying muscle fiber detachment following incubation in methyl cellulose (Figure 3).

Figure 3. Atrogin-1 mutants display increased levels of BiP, which is sufficient to cause muscle fiber detachment. (A) Volcano plot highlighting differentially regulated proteins in atrogin-1–/– larvae compared with atrogin-1+/+ wild-type larvae – identified from untargeted proteomics. Proteins significantly (q < 0.05) upregulated and downregulated are shown in red and blue, respectively, as determined using an unpaired t test. (B) Representative Western blot images for BiP and total protein direct blue stain, on whole cell protein lysates obtained from 3 independent biological replicates, each containing multiple atrogin-1–/– or atrogin-1+/+ larvae. (C) Quantification of BiP levels normalized to total protein in atrogin-1–/– larvae displaying a significant reduction compared with atrogin-1+/+, as determined using an unpaired t test. Data are shown as mean ± SD. (D–F) 6 dpf tunicamycin- (Tm-) or thapsigargin-treated (Tg-treated) larvae display muscle fiber detachment following incubation in methyl cellulose. (G) The percentage of affected larvae, with Tm or Tg treatment resulting in a significant increase in the proportion of fish displaying the muscle fiber detachment, as determined using a χ² test. (H and I) Confocal images of F-actin–stained, methyl cellulose–treated, 6 dpf atrogin-1–/– mutants on the Tg(actc1b:KalTA4;crya:GFPpc54) only [labeled as Control (KalTA4)] or Tg(actc1b:KalTA4;crya:GFPpc54) and Tg(4XUAS:NLSCas9;cml2:RFP gl37) (labeled as BiP KO) background. While control atrogin-1–/– mutants display fiber detachment, atrogin-1–/– mutants with BiP deficiency specifically in the muscle show normal muscle structure. (J) The percentage of affected atrogin-1–/– control larvae and BiP-KO larvae, with the latter having a significant decrease in the proportion of fish displaying the muscle fiber detachment, as determined using Fisher’s exact test. *P < 0.05, **P < 0.01. All experiments performed in triplicate with the total number of fish examined in each replicate being documented in Supplemental Table 2. Scale bar: 200 μm.
(Figure 3, D–G), consistent with the morphology seen in the atrogin-1−/− mutants. Therefore, chronic ER activation of ER stress can explain the characteristic phenotype evident in the atrogin-1−/− mutant.

To more explicitly implicate BiP accumulation as the mechanism responsible for the muscle fiber detachment seen in the atrogin-1−/− mutant, we made use of the compound HM03, which has been shown to selectively inhibit BiP activity by binding to its substrate binding domain (19). We treated 3 dpf atrogin-1−/− mutants with the BiP inhibitor HM03 or DMSO for 3 days, changing the chemical each day thereafter, and at 6 dpf we examined muscle integrity. Although the rescue was not complete, pharmacological inhibition of BiP resulted in a reduction in the number of atrogin-1−/− mutants displaying fiber disintegration (Supplemental Figure 2, D–F), supporting the role of BiP accumulation in driving the myopathic phenotype seen following atrogin-1 deficiency.

As an alternative approach, we attempted to generate a BiP mutant line using CRISPR/Cas9 genome editing. However, despite using low levels of BiP targeting guide RNAs, BiP crispant larvae displayed striking phenotypes, including edema in the brain and heart (Supplemental Figure 3, A and B) that were lethal and thus limited our ability to recover BiP germine mutants. Indeed, mice that are completely deficient in BiP display peri-implantation lethality (20). To overcome this issue, we developed a muscle-specific BiP-KO strategy to examine its ability to rescue the atrogin-1−/− mutant phenotype. Briefly, this involves the use of two transgenic lines on the atrogin-1−/− mutant background: a muscle-specific KalTA4 expressing line (Tg(actc1b:KalTA4;cryaa:GFPpc54Tg) crossed to a UAS-driven Cas9 line (Tg(4XUAS:NLSCas9;cmlc2:RFP gl37Tg) (Supplemental Figure 3C). Into this line, we injected two BiP-targeting guide RNAs at the 1-cell stage, which is predicted to result in muscle-specific mutagenesis of BiP (BiP KO) and subsequent loss in expression. To confirm the loss of BiP expression, we stained 3 dpf BiP-KO fish with antibody against myosin and BiP. While 89% of control fish, which were injected with the dual BiP gRNAs but lack KalTA4, displayed striated ER-like BiP localization, only 27% of BiP-KO fish showed clear striations, with the remaining 73% lacking this staining pattern (Supplemental Figure 3, D–F), confirming the loss of BiP expression. To further support this, examination of BiP levels using Western blot on whole cell lysates demonstrated a significant reduction of BiP in BiP-KO fish compared with control fish (Supplemental Figure 3, G and H). Collectively, these results confirm that our tissue-specific approach results in a reduction in BiP expression in the muscle.

Having confirmed the efficiency of our tissue-specific KO approach, we examined the muscle morphology in 6 dpf BiP-KO, atrogin-1−/− mutant larvae. Remarkably, muscle-specific KO of BiP resulted in a striking rescue of the fiber integrity defects of atrogin-1−/− mutant larvae (Figure 3, H–J). While 56% of atrogin-1−/− mutants displayed detached muscle fibers, this was significantly reduced to 21% following muscle-specific loss of BiP in atrogin-1−/− mutants (Figure 3J). A potential explanation for this rescue is that muscle-specific loss of BiP results in reduced muscle contraction, thus preventing fiber detachment. To exclude this possibility, we examined locomotor function, using the Zebrabox assay — which examines the average distance, time, and, thus, speed a fish moves over a 10-minute period — of 6 dpf, BiP-KO larvae. As shown in Supplemental Figure 3I, the average speed traveled by BiP-KO larvae is indistinguishable from that of control larvae, highlighting that muscle-specific loss of BiP does not affect motor performance. Taken together, these results highlight a role of atrogin-1–mediated BiP regulation in the maintenance of muscle homeostasis.

Systems proteomics reveals impaired mitochondrial dynamics as the mechanism of muscle fiber detachment in atrogin-1–deficient fish. While our results support a model in which BiP accumulation results in fiber detachment

<table>
<thead>
<tr>
<th>Protein name</th>
<th>UniProt ID</th>
<th>Fold change in atrogin-1−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td>bip</td>
<td>Q6P3L3</td>
<td>1.56</td>
</tr>
<tr>
<td>gars</td>
<td>F1QUV7</td>
<td>1.24</td>
</tr>
<tr>
<td>flncb</td>
<td>F1QL44</td>
<td>1.18</td>
</tr>
<tr>
<td>smyhc1</td>
<td>A0AR4IN13</td>
<td>1.17</td>
</tr>
<tr>
<td>ckma</td>
<td>A2BHA3</td>
<td>1.16</td>
</tr>
<tr>
<td>cct2</td>
<td>Q6PBW6</td>
<td>1.15</td>
</tr>
<tr>
<td>myom1b</td>
<td>A0AR4IGQ8</td>
<td>1.02</td>
</tr>
</tbody>
</table>
in atrogin-1 mutants, we wished to determine how this was regulated at a cellular level. To this end, we reexamined our atrogin-1 mutant proteomics data set to identify any potential pathways that may be dysregulated in the mutant. Enrichment analyses on all differentially regulated proteins in atrogin-1−/− larvae revealed a significant overrepresentation of proteins of the oxidative phosphorylation (OXPHOS) pathway (Figure 4A), which is responsible for the production of ATP in the mitochondria. Further examination of proteins within this Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway revealed that except for atp6v1ab and atp5f1b, all other proteins (ndufb6, ndufa10, ndufs3, cox4i1, cox5aa, atp5pb, atp6v1e1b, and atp5fa1) were downregulated in atrogin-1−/− larvae compared with atrogin-1+/+ larvae (Figure 4B). One possible explanation for this is the reduced transcription of each of these complexes. However, our qRT-PCR analyses revealed small, nonsignificant increases in expression of each of these genes, highlighting that reduced transcription is not responsible for the reduction in OXPHOS abundance observed in atrogin-1−/− deficient larvae (Supplemental Figure 4A). An alternative explanation for the changes in OXPHOS levels is a change in mitochondrial fission and fusion rates and the subsequent reduction in mitochondria number. To assess mitochondrial fusion and fission, we examined the expression of mitochondrial fission genes drp1 and fis1 and fusion genes mfn1, mfn2, and opa1. With the exception of opa1, all genes examined were significantly downregulated in the atrogin-1 mutant, suggestive of altered mitochondrial dynamics (Supplemental Figure 4, B and C). We also examined total mitochondrial content, using Western blot for VDAC1 on whole cell protein lysate, and, in line with our hypothesis, atrogin-1−/− larvae displayed a significant reduction in VDAC1 levels compared with atrogin-1+/+ larvae, indicating a reduction in mitochondrial content (Figure 4, C and D).

Having identified altered mitochondrial biology in the atrogin-1 mutant, we wished to further characterize their mitochondrial structure and function. Mitochondrial morphology was examined by expressing a mito-GFP construct (generated by fusing the mitochondrial targeting sequence of Cox8a to GFP) specifically in the muscle of methyl cellulose–treated atrogin-1+/+ wild-type and atrogin-1−/− mutants. To this end, we treated 3 dpf wild-type larvae with rotenone, a complex 1 inhibitor, for 3 days and examined the muscle using an antibody against F-actin. Remarkably, while DMSO treatment had no effect on muscle integrity (Supplemental Figure 4D), chronic inhibition of mitochondrial function resulted in muscle fiber detachment (Supplemental Figure 4, E and F), consistent with this, electron microscopy revealed that 6 dpf methyl cellulose–treated atrogin-1−/− mutants displayed fiber disintegration, evident by the disorganized arrangement of sarcomeres and abnormal mitochondria with large and swollen matrices (Figure 4, L, M, and O), with methyl cellulose–treated atrogin-1−/− larvae displaying large and rounded mitochondria (Figure 4, G, I, and N). Finally, oxygen consumption rates, a readout of mitochondrial function, were also examined in the atrogin-1−/− deficient larvae. We report a significant reduction in both basal (Figure 4N) and maximum respiration (Figure 4O) in 3 dpf methyl cellulose–treated atrogin-1−/− mutant larvae, indicating an alteration in mitochondrial function. Collectively, these results highlight that loss of atrogin-1 results in a reduction in mitochondria number and an impairment in mitochondrial structure and function.

We next wished to determine if the mitochondrial alterations observed could explain the muscle fiber detachment phenotype seen in atrogin-1−/− mutants. To this end, we treated 3 dpf wild-type larvae with rotenone, a complex 1 inhibitor, for 3 days and examined the muscle using an antibody against F-actin. Remarkably, while DMSO treatment had no effect on muscle integrity (Supplemental Figure 4D), chronic inhibition of mitochondrial function resulted in muscle fiber detachment (Supplemental Figure 4, E and F), identical to the phenotype seen in atrogin-1−/− mutants. These results highlight that impaired mitochondrial dynamics is sufficient to cause muscle fiber detachment.

**BiP accumulation is responsible for impaired mitochondrial biology.** To determine if the mitochondrial phenotypes seen in the atrogin-1 mutant are caused by BiP accumulation, we treated 3 dpf larvae expressing the mito-GFP transgene with Tm or Tg for 3 days and examined mitochondrial morphology. Our analyses revealed that chronic treatment with Tm or Tg resulted in a significant increase in the proportion of muscle fibers displaying large and rounded mitochondria compared with those in F-actin DMSO–treated animals (Figure 5, A–G), consistent with the morphology seen in the atrogin-1−/− mutants. To more explicitly implicate BiP accumulation as the mechanism responsible for the mitochondrial phenotypes seen in the atrogin-1 mutant, we generated a construct to enable the muscle-specific overexpression of fluorescently tagged, full-length mouse BiP. To confirm that the fluorescently tagged form of BiP localized correctly to the ER, we stained BiP-mCherry–expressing fish with an anti-mCherry antibody and with an antibody against Ryr1, which is known to localize within the t-tubule. Using super resolution imaging, BiP-mCherry was found to localize to the terminal cristae of the sarcoplasmic reticulum (SR), a structure
directly adjacent to the T-tubules, and more generally within the SR network (Supplemental Figure 5, A–C). Having confirmed that fluorescent tagging of BiP does not affect its localization, we coinjected the BiP-mCherry construct (or mCherry alone) along with the mitochondria labeling GFP plasmid to examine the effect of BiP overexpression on mitochondrial structure. Remarkably, while mCherry-expressing muscle cells displayed small, intricate mitochondrial networks (Figure 4I and Figure 5, H–K), BiP-mCherry–expressing fibers had predominantly large and rounded mitochondria that phenocopied the atrogin1 loss-of-function phenotype (Figure 5, L–O and P). This demonstrates that BiP upregulation alone is sufficient to cause the abnormal mitochondrial structure observed in the atrogin-1–deficient fish.
As a final approach, we used our muscle-specific BiP-KO system to examine if loss of BiP is sufficient to rescue the mitochondrial phenotype seen in the atrogin-1 mutant. Indeed, while 56% of muscle fibers in atrogin-1–/– mutant larvae contained large and rounded mitochondria, this was significantly reduced to 22% in BiP muscle–specific KO, atrogin-1–/– mutants, highlighting a rescue in the mitochondrial phenotypes (Figure 5, Q–S).

We next wished to determine if BiP overexpression altered mitochondrial dynamics as seen in the atrogin-1–/– mutant. To this end, wild-type embryos were injected with mCherry or BiP-mCherry RNA, and at 2 dpf qRT-PCR for UPR and mitochondrial fission and fusion genes was performed. Consistent with the injection of RNA, BiP-mCherry–injected fish displayed increased levels of BiP (Supplemental Figure 5D). Interestingly, we also observed a significant increase in the expression of atf4, with chop showing a small nonsignificant increase, suggesting that BiP overexpression may have triggered ER stress (Supplemental Figure 5D). Furthermore, in line with the reduced expression of mitochondrial fission and fusion genes observed in atrogin-1–/– mutants, BiP-mCherry RNA–injected larvae displayed a significant reduction in drp1, fis1, mfn2, and opa1, with mfn1 showing small but nonsignificant reduction (Supplemental Figure 5, E and F), highlighting a role of BiP in regulation mitochondrial dynamics.

Taken together, our results demonstrate that the loss of atrogin-1 results in the accumulation of BiP, which results in mitochondrial dysfunction and a subsequent detachment and apoptosis of muscle cells.

Atrogin-1 is a modifier in, and contributes to, the pathogenesis of DMD. The muscle fiber detachment observed in the atrogin-1–/– mutant is strikingly similar to the phenotype seen in zebrafish models of DMD, caused by a mutation in dystrophin (21). Given that our findings have implicated BiP accumulation in the presentation of the atrogin-1–/– mutant phenotype, we hypothesized that a similar mechanism may be contributing to the
pathogenesis of DMD. Indeed, BiP upregulation has been reported in several mammalian models of DMD (22, 23), but whether a similar response occurs in zebrafish is not known. To determine this, we performed Western blotting for BiP on whole cell lysates of 2 dpf and 4 dpf dmd<sup>++/−</sup> wild-type and dmd<sup>−/−</sup> mutant larvae. Consistent with the mammalian models, we observed a significant increase in BiP expression in 4 dpf dmd<sup>−/−</sup> mutant compared with the dmd<sup>++/−</sup> wild-type larvae, although no change was observed at 2 dpf (Figure 6, A and B). To determine if loss of dystrophin results in increased ER stress and activation of the UPR, we performed qRT-PCR for the UPR genes bip, chop, a66, and af4. We observed a significant increase in the expression of bip and af6, with chop and af4 showing small but nonsignificant increases (Supplemental Figure 6A). Therefore, as shown in the mdx mouse model, and in skeletal muscle from patients with DMD (22–24), the loss of dystrophin in zebrafish also results in increased abundance of BiP and activation of the UPR.

Having confirmed that BiP is upregulated in zebrafish models of DMD, we wished to determine if the atrogin1-BiP axis we have identified contributes to DMD pathology and could be manipulated for potential therapeutic gain. As such, we crossed the dmd<sup>−/−</sup> mutant with the atrogin1-IRES-GFP mutant and examined muscle structure, using birefringence assays and locomotor function in the double mutants. As previously shown, dmd<sup>−/−</sup> mutants displayed a significant reduction in mean birefringence intensities compared with wild-type larvae (Figure 6, C, D, and G), highlighting a reduction in muscle fiber integrity. The birefringence intensities in atrogin1-IRES-GFP mutants on the other hand were indistinguishable from those of wild-type larvae (Figure 6, C, E, and G), consistent with the mild, sporadic phenotypes seen in these mutants. Simultaneous loss of both dystrophin and atrogin-1 resulted in a dramatic additive reduction in birefringence intensity within the myotomes of double mutant larvae, compared not only with wild-type and atrogin1-IRES-GFP mutants, but also dmd<sup>−/−</sup> mutants (Figure 6, C, F, and G). This highlights a potential role of atrogin-1 in modifying the muscle fiber detachment in DMD. We also examined if loss of atrogin-1 affects muscle function in dmd<sup>−/−</sup> mutants, specifically examining the average speed of larvae over a 10-minute period in a standard zebrafish locomotion assay (25). Similar to the birefringence assays, while dmd<sup>−/−</sup> mutants have a significant reduction in average speed, it is further reduced following the loss of atrogin-1 (Figure 6H). The exacerbation of the muscle detachment phenotype and reduction in muscle function in dmd<sup>−/−</sup> mutants following the loss of atrogin-1 demonstrates a role of the latter in DMD pathogenesis.

As further validation of atrogin-1’s role in DMD, we injected atrogin1-IRES-GFP (or GFP control) RNA in dmd<sup>−/−</sup> mutants and examined muscle fiber integrity in 4-day-old animals. Expression of RNA was confirmed by the fluorescence of GFP protein in the myotome of injected larvae (Figure 6, I and J). atrogin1-IRES-GFP mRNA injection significantly ameliorated the reduction in birefringence intensity evident in dmd<sup>−/−</sup> larvae, although the rescue was not complete — that is, atrogin1-IRES-GFP-injected dmd<sup>−/−</sup> mutants still has a significant reduction in birefringence compared with dmd<sup>++/−</sup> wild-type larvae injected with same RNA (Figure 6, K–O). This is a surprising finding, because it suggests that in DMD additional dystrophin-independent mechanisms regulated by atrogin-1 may be contributing to disease pathogenesis. Importantly, atrogin-1 overexpression did not have any detrimental effect on muscle integrity, as evident by indistinguishable birefringence intensities between GFP-injected and atrogin1-IRES-GFP injected wild-type larvae (Figure 6, K–O). These results combined with the data on the dmd<sup>−/−</sup>; atrogin1-I−/− double mutants implicates atrogin-1 in the presentation of DMD pathologies.

**BiP inhibition rescues muscle function in DMD.** While our results suggest that atrogin-1 may be manipulated for therapeutic gain in DMD, we wanted to examine whether manipulating levels of BiP, which is regulated by atrogin-1, could provide a possible alternative therapeutic strategy to combat DMD. To test this, we treated 3 dpf dmd<sup>++/−</sup> wild-type larvae and dmd<sup>−/−</sup> mutants with the BiP inhibitor HM03, or DMSO control for 3 days, changing the chemical each day thereafter, and at 6 dpf we performed muscle integrity birefringence assays and zebrafish assays. Contrary to our hypothesis, HM03 treatment had no effect on muscle integrity, evident from the indistinguishable birefringence intensities between DMSO-treated and HM03-treated dmd<sup>−/−</sup> mutants (Figure 7, A–D). We confirmed this result by treating dmd<sup>−/−</sup> mutants on the Tg(actc1b:Lifeact-GFP);Tg(actc1b:CAAX-mCherry) background, whereby the actin filaments within the muscle fibers were labeled with GFP and membrane and t-tubules with mCherry (Supplemental Figure 6, B–D). Similar to the birefringence assays, HM03-treated dmd<sup>−/−</sup> mutants displayed similar severities of fiber detachment to DMSO-treated dmd<sup>−/−</sup> mutants. While these results are surprising, they suggest that rescue of muscle fiber integrity in the dmd<sup>−/−</sup> following atrogin-1 overexpression likely results from an atrogin-1 target independent of BiP.

We also examined the effect of HM03 treatment and subsequent BiP inhibition on the muscle function of dmd<sup>−/−</sup> mutants. Unlike the results for muscle integrity, HM03 treatment significantly improved the average
speed of dmd–/– mutants compared with DMSO-treated dmd–/– larvae (Figure 7E). Remarkably, the mean speed of HM03-treated dmd–/– mutants was comparable to that of DMSO-treated dmd+/+ wild-type larvae, indicating that HM03 completely restored muscle function in the mutant fish (Figure 7E). Importantly, treatment of dmd+/+ wild-type larvae with HM03 had no effect on their speed, demonstrating that the improvement in muscle function seen in dmd–/– mutants was specific and not a generalized response.

Together, these results demonstrated that HM03 and the subsequent inhibition of BiP specifically improves muscle function in performance in dmd–/– mutants. Therefore, while the atrogin-1–mediated BiP may not be involved in the loss in fiber integrity seen in DMD, it does contribute to the reduction in muscle function, making this disease axis therapeutically relevant for potentially improving muscle performance in boys with DMD.

**Discussion**

In the current study, we characterized the skeletal muscle of zebrafish deficient in atrogin-1, an E3 ubiquitin ligase that is upregulated in numerous muscle wasting conditions. We reveal that the loss of atrogin-1 resulted in the detachment and apoptosis of skeletal muscle fibers — consistent with the myopathic phenotypes seen following the transient knockdown of atrogin-1 — and displayed striking defects in mitochondrial structure and function (9). Using a systems proteomics approach, we further reveal that these phenotypes are attributed to the accumulation of BiP, the master regulator of ER/SR, which results in impaired mitochondrial dynamics and a subsequent detachment of muscle fibers. Atrogin-1 is therefore not only important in regulating catabolic processes but may also be indirectly regulating broader ER and mitochondrial regulated processes critical for the maintenance of muscle fiber integrity. It is noteworthy that, while the current study focused on characterizing this function of atrogin-1, our proteomics data set also identified some of the previously characterized targets of atrogin-1, including myosin and desmin (15).
to be differentially regulated. Therefore, in addition to interacting with and regulating levels of sarcomeric proteins, and other proteins such as transcription factors and proteins of the ubiquitin proteasome system and autophagy/lysosome system, our study provides evidence of atrogin-1’s involvement in regulating ER-related cellular processes. Additionally, while there was a clear overlap in differentially regulated proteins identified in skeletal muscle lacking atrogin-1 (this study) and in cardiomyocytes deficient in atrogin-1 (12), there were also proteins that were unique to each tissue. This suggests that atrogin-1 and potentially other E3 ubiquitin ligases have specific targets that may differ across different tissues. Collectively, our results highlight a requirement of atrogin-1 in maintaining muscle homeostasis and suggest that its inhibition may result in dysregulation of ER- and mitochondrial-related processes. This is particularly relevant to therapies that aim to ameliorate muscle wasting by inhibiting atrogin-1. Our results suggest that, while short-term atrogin-1 inhibition may be beneficial, chronic inhibition is expected to be deleterious, resulting in ER defects, mitochondrial impairment, and a loss in muscle fiber integrity. Indeed, atrogin-1 mutations have recently been shown to cause dilated cardiomyopathy due to the upregulation of ER-stress–mediated apoptosis (26), supporting the unsuitability of atrogin-1 inhibition in treating muscle wasting.

The muscle fiber detachment observed following the loss of atrogin-1 is strikingly similar to the phenotype seen in zebrafish models of DMD (21), caused by a mutation in dystrophin, suggesting that atrogin-1 and BiP may contribute to the pathogenesis of the disease. Contrary to findings of previous studies, which showed amelioration of DMD pathology in zebrafish using the ubiquitin-proteasome system inhibitor MG132 (27), we showed that loss of atrogin-1 exacerbates the DMD phenotype and that upregulation can rescue muscle pathology. The latter is a highly surprising finding, because it suggests that in DMD additional dystrophin-independent mechanisms may be contributing to muscle fiber detachment, which can be ameliorated by increasing atrogin-1 levels, thus providing alternative therapeutic approaches for DMD. Consistent with this idea, cardiomyocyte-specific upregulation of atrogin-1 has been shown to reduce collagen deposition and fibrosis in the aged heart (28). Further studies to identify specific inducers of atrogin-1 and their use in treating DMD and potentially other muscle diseases are therefore needed.

In addition to targeting atrogin-1, our work has revealed BiP inhibition as an alternative strategy for the treatment of DMD. We observed a striking increase in BiP in the zebrafish DMD model, which is consistent with the upregulation seen in mammalian models of DMD (22, 23). Previous studies have shown that increased levels of BiP and of ER stress in general result in an impairment in the crosstalk between the SR and mitochondria, which subsequently disrupts calcium handling (22). Based on this, we propose that BiP accumulation has similar consequences in skeletal muscle of dystrophin-deficient zebrafish and that the specific inhibition of BiP may provide an alternative therapeutic strategy. To test this, we used the compound HM03, identified from cascade in silico screening, to specifically inhibit BiP by binding to its substrate binding domain and subsequently inhibiting cancer and tumour cell viability (19). Consistent with this improvement in a cancer setting, the specific inhibition of BiP using HM03 resulted in significant rescue...
in muscle function in dystrophin-deficient zebrafish. One caveat is that the locomotory assays utilized are also a read-out of neuromuscular function. Therefore, the improvements in muscle function noted following HM03 treatment could also be due to changes in other nonautonomous systems, such as motor neuron function. Importantly, while BiP inhibitors have previously not been tested in DMD, treatment of mdx mice with the ER chaperone taurosodeoxycholic acid (TUDCA) has been shown to reduce ER stress and restore the SR-mitochondria interaction and calcium dynamics, subsequently improving contractile function. Furthermore, KO of caspase-12, a downstream effector of the UPR in mdx mice restores muscle force, emphasizing the role of ER stress in DMD pathology (23). It is noteworthy that, while atrogin-1 overexpression resulted in an unexpected improvement in muscle pathology, HM03 had no effect. This discrepancy could be explained by the incomplete inhibition of BiP by HM03 treatment, which is supported by the lack of severe BiP crispant-like phenotypes in the HM03-treated fish. An alternative explanation is that the rescue in muscle fiber integrity seen in dystrophin-deficient zebrafish following atrogin-1 overexpression likely results from an atrogin-1–mediated mechanism independent of BiP. In any case, the ability to fully rescue muscle function using HM03 suggests that BiP is the primary contributor to the reduction in muscle function in DMD and provides a more specific target than the previously tested TUDCA for improving muscle function in DMD. Upregulation of BiP and ER stress/UPR–related factors is also observed in several other types of muscle diseases (reviewed in ref. 29), including limb-girdle muscular dystrophy caused by mutations in FKRP (30, 31) and caveolin 3 (32), sporadic inclusion body myositis caused by mutations in GNE (33), and tibial muscular dystrophy caused by mutations encoding Titin (34). Inhibition of BiP using HM03 or alternative approaches may therefore also be relevant for the treatment of these disorders.

In conclusion, we have identified a role of atrogin-1–mediated BiP regulation in the pathogenies of DMD. While the inhibition of BiP resulted in a striking rescue in the muscle function, it had no effect on muscle pathology. This is a remarkable finding because it highlights that the reduction in muscle function and loss in muscle fiber integrity are caused by different cellular processes. As such, while corrective gene therapies to restore dystrophin expression and subsequently correct muscle attachment lie on the horizon, deficits in muscle contractile and metabolic function may persist even after successful transduction. Approaches, such as those highlighted in the current study, including atrogin-1 upregulation or BiP inhibition, will likely be needed to complement gene-based interventions for the treatment of DMD and other muscle wasting disorders.

Methods

Sex as a biological variable. Given that sex is undetermined in zebrafish larvae, sex was not considered as a biological variable.

Fish maintenance. Briefly, adult zebrafish were maintained in recirculating aquarium systems and were kept between 26°C and 28°C on a 14-hour-light/10-hour-dark cycle. Fish were differentially fed according to their age: larvae (up to 10 dpf) were fed paramecia twice daily; larvae (10–14 dpf) were fed paramecia twice daily and a single feed of Artemia salina; juveniles (10–30 dpf) were fed Artemia salina twice daily; and fish aged 30 days and older were fed Artemia salina twice daily and appropriate sized pellets. Animals were group housed in 3 L tanks, with a maximum of 6 fish per liter. The health of the fish was monitored on a daily basis. All experiments were carried out on embryos of TU/TL background. Fish were anesthetized using Tricaine methanesulfonate (3-amino benzoic acid ethylester; MilliporeSigma, E10521) at a final concentration of 0.16% in E3 embryo medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl, 0.33 mM MgSO4, 0.00004% [v/v] methylene blue in water, pH 7.2). To exacerbate the loss in muscle integrity in atrogin-1–/– mutants, larvae were incubated in 1% methyl cellulose for 2 hours, as per refs. 35, 36, and subsequently fixed and processed for immunofluorescence.

Generation of plasmids and transgenic and mutant strains. Vectors for transgenesis were generated using the Tol2kit system (37). Briefly, 3 entry clones (5′, middle, and 3′) were recombined into a fourth destination vector backbone. The muscle-specific mito-GFP construct (actc1b-mito-GFP) was generated using pSE-actc1b (38), pME-mitoGFP (this study), and p3E-PA and pDEST-Tol2-pA2 (37). Actc1b-KalTA4 (39) was also made using p5E-actc1b and p3E-PA but used pME-KalTA4 (39) as the middle entry clone and a modified destination vector that had a GFP lens reporter (pDEST-Tol2-pA2-aCry-EGFP) (40). The atrogin-1-IRESCGF plasmid was generated with p5E-CMV/SP6 (37), full-length zebrafish atrogin-1 in the middle entry position (pME-atrogin-1; this study), and IRES-GFP in the 3′ position (37). pME-mitoGFP contains the first 31 amino acids of the zebrafish cytochrome c oxidase subunit 8A (cox8a) sequence fused to GFP (41). This vector was produced by subcloning the mito-GFP sequence from the original MLS-EGFP vector (41) into
μng/ase, MilliporeSigma) were injected into single-celled zebrafish embryos at a final concentration of 50 ng/μL into 1-cell-stage embryos. Injected embryos were sorted for GFP labeling prior to analysis.

The atrogin-1 mutant strain (atrogin-1<sup>−/−</sup>) was generated using the CRISPR/Cas9 system. Synthetic gRNAs targeting atrogin-1 were generated as crRNA:tracrRNA duplexes (Alt-R CRISPR–Cas9 system, IDT). The following atrogin-1 targeting crRNA sequence, identified using the ZiFIT program, with PAM sequences in uppercase letters, was used: 5′-ggacaagaagccgcttcgATG-3′. The atrogin-1 targeting crRNA was heteroduplexed to universal tracrRNA according to the manufacturer’s protocol to generate bipartite gRNAs, which was subsequently was injected into one-cell-stage embryos, along with Cas9 crRNA was heteroduplexed to universal tracrRNA according to the manufacturer’s protocol to generate bipartite gRNAs, which was subsequently was injected into one-cell-stage embryos, along with Cas9 and Cascade Blue dye (Molecular Probes, D1976). Primers used for the generation and genotyping of the atrogin-1<sup>−/−</sup> mutant strain are listed in Supplemental Table 3. An additional atrogin-1 mutant strain (atrogin-1<sup>pc44/pc44</sup>) was generated using Zinc-finger nuclease technology. mRNAs encoding a pair of Zinc-finger nucleases targeted to exon 4 of the atrogin-1 locus (CompoZr Knockout Zinc Finger Nuclease, MilliporeSigma) were injected into single-celled zebrafish embryos at a final concentration of 50 ng/μL. Allele-specific PCR KASP technology (Geneworks) was used for atrogin-1<sup>−/−</sup> genotypeotyping. For tissue-specific KO of BiP, bipartite BiP targeting gRNA sequences were designed using the IDT Alt-R CRISPR-Cas9 guide RNA tool. Specificity was examined in silico, and sequences that had high on-target and low off-target scores were selected. Specificity was also examined using the BLAST tool, and gRNA sequences that matched BiP with high confidence (low E value) and no other loci were selected. To achieve muscle-specific knockdown of BiP, Tg(actc1b:KalTA4; cryaa:GFP<sup><sub>pc44</sub></sup>) was crossed to Tg(4X-UAS:NLSCas9; cmc2:RFP<sup>6377G</sup>) (each line on the atrogin-1<sup>−/−</sup> mutant background), and in the resulting embryos, 2 BiP targeting bipartite gRNAs (listed in Supplemental Table 1) were injected at the 1-cell stage. At 3 dpf, the fish were sorted for green lens and red hearts to confirm the presence of cryaa:GFP and cmc2:RFP linked to actc1b: KalTA4 and actc1b:4XUAS:NLSCas9, respectively. Existing mutant and transgenic lines used include: dmb<sup>actc1b</sup> (21), Tg(actc1b:mCherry-CAAX)<sup>576</sup> (42), Tg(actc1b:lifect-GFP)<sup>576</sup> (42), and Tg(4X-UAS:NLScas9, cmc2:RFP<sup>6377G</sup>) (43). With the exception of electron microscopy experiments, seahorse assays, and HM03 drug rescue on the atrogin-1 mutant, heterozygous adults were crossed to generate a pool of homozygous wild-type and heterozygous and homozygous mutant larvae, and different parents were used for each replicate. For electron microscopy, seahorse assays, and HM03 drug rescue experiments on the atrogin-1 mutant, atrogin-1<sup>−/−</sup> wild-type or mutant adults were crossed to obtain aged-matched larvae for each of the experiments, and different parents were used for each replicate.

Immunofluorescence and quantitative RT-PCR. Zebrafish immunofluorescence experiments were performed according to previously published protocols (44). The following antibodies/vital dyes were used in this study: Rhodamine-tagged phalloidin (Molecular Probes, 1:200), anti-BiP (MilliporeSigma, G9043, 1:500), and anti-Ryr1 (MilliporeSigma, R129, 1:100). The primary antibody was washed at least 6 times with PBST, following which the samples were incubated in appropriate secondary antibodies: Alexa Fluor–labeled 488, Alexa Fluor–labeled 564, and/or Alexa Fluor–labeled 596 (Invitrogen, 1:300). Stained embryos were mounted in 1% low-melting-point agarose and imaged using a Zeiss LSM 710 confocal microscope (phalloidin and TUNEL stains, Evans Blue Dye labeling) or Zeiss LSM 980 confocal microscope with super-resolution Airyscan 2 (BiP stained). The maximum intensity projections were obtained using Fiji (http://fiji.sc). The phenotype was scored prior to performing genotyping assays to ensure the researcher was blinded to the genotype.

cDNA synthesis and quantitative RT-PCR. Total RNA was extracted using TRI Reagent (MilliporeSigma). cDNA was synthesized by Superscript III Reverse Transcriptase (Invitrogen Life Technologies). Quantitative RT-PCR (qRT-PCR) was performed using a Lightcycler (Roche) using SYBR Green Master mix (Roche). Primers used for RT-PCR analysis are listed in Supplemental Table 3.

RNA synthesis. For atrogin-1 RNA rescue experiments, GFP or atrogin-1-ires-GFP RNA was synthesized using the mMessage mMachine SP6 Transcription Kit (Ambion). RNA was injected at a concentration of 50 ng/μL into 1-cell-stage embryos. Injected embryos were sorted for GFP labeling prior to analysis.
TUNEL staining. 6 dpf methyl cellulose–treated fish were fixed in 4% paraformaldehyde (PFA) for 2 hours at room temperature. The fixed fish were washed twice with PBST (137 mM NaCl, 2.7 mM KCl, 10 mM NaHPO4, 1.8 mM KH2PO4 and 0.1% [w:v] Tween 20 [MilliporeSigma Aldrich, P9416]) and then stored overnight in 100% methanol at -20°C. On the next day, embryos were incubated in precooled 100% acetone for 10 minutes at -20°C, following which they were washed with PBST 3 times, for 10 minutes each. The embryos were then permeabilized with 0.1% Triton X-100 and 0.1% sodium citrate in PBS for 15 minutes. TUNEL staining was then performed as per manufacturer’s protocol (In Situ Cell Death Detection Kit, POD, Roche, 1168417910). To achieve a brighter signal, TUNEL-stained embryos were blocked in blocking solution (10% fetal calf serum, 0.1% Tween 20, and 1% DMSO in PBS) for 1 hour and stained with an anti-fluorescein antibody (Roche, 1426346910, 1:2000) overnight at 4°C. The next day, the embryos were washed 8 times in PBST and stained with an appropriate secondary antibody (Alexa Fluor 488 donkey anti-sheep antibody, Life Technologies, A11015, 1:300) overnight at 4°C. Finally, the embryos were washed 8 times in PBST and imaged using a Zeiss LSM 710 confocal microscope.

Evans blue dye injections. A working injection mix (0.1% Evans blue dye) was diluted using Ringer’s solution prior to injection of 5 nL into the pericardial vein of 6 dpf larvae obtained from a heterozygous incross. After injection, zebrafish embryos were placed in Ringer’s solution and incubated in the dark at 28°C for 3 hours, following which they were incubated in 1% methyl cellulose for 2 hours to induce fiber damage. Larvae were subsequently mounted in 1% low-melting-point agarose and imaged using a Zeiss LSM 710 confocal microscope.

Electron microscopy. 6 dpf zebrafish larvae were fixed in 2.5% glutaraldehyde, 2% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, overnight at 4°C. After washing in 0.1 M sodium cacodylate tissue was post-fixed in 2% osmium tetroxide in 0.1 M sodium cacodylate, rinsed in distilled water, and then dehydrated in acetone and embedded in Epon using a Pelco Biowave Pro. After polymerization, ultrathin sections (90 nm) were cut using an Ultracut Leica Ultramicrotome and stained with 2% uranyl acetate in distilled water and lead citrate. The sections were imaged with a Jeol 1400Plus TEM.

Cell culture and transfection. HEK293T cells were grown in DMEM supplemented with 1% antibiotics and 10% fetal bovine serum. About 14 μg of vectors containing the constructs were used to transfect the cells using the Lipofectamine 3000 (Gibco, Thermo Fisher Scientific, L3000001) following the manufacturer’s instructions. Briefly, before transfection, the cell media were replaced with Opti-MEM (Gibco, Thermo Fisher Scientific, 31985062). DNA was mixed with P3000 Reagent in Opti-MEM and Lipofectamine 3000 Reagent was diluted in Opti-MEM. The DNA mix was added to the Lipofectamine mix and incubated at room temperature for 20 minutes. The DNA/Lipofectamine complex was added to the cells, and media were changed after 12 hours. After 24 hours, as control cells showed high GFP expression, total protein was extracted. Transfected cells were lysed with an IP Lysis buffer (Pierce, Thermo Fisher Scientific, 8788) and protease inhibitors (Roche, MilliporeSigma, 11836170001) and then centrifuged at 13,800 g for 20 minutes at 4°C. Lysates were stored at -80°C before use for immunoprecipitation or Western blot.

Immunoprecipitation. All the steps required for immunoprecipitation were carried out using the DynaMag-Spin Magnet (Invitrogen, Thermo Fisher Scientific, 12320D) following the c-Myc-Tag Magnetic IP/Co-IP Kit manufacturer’s instructions (Pierce, Thermo Fisher Scientific, 8844). Briefly, 1 mL anti-Myc antibody–conjugated magnetic beads was incubated overnight at 4°C. After several washes, the adsorbed protein was eluted with 30 μL elution buffer, incubated at 100°C, and run on a SDS/PAGE followed by Western blot analysis with an anti-Myc antibody (Invitrogen, Thermo Fisher Scientific, PA1-981, 1:2000) and anti-HA antibody (Progen, Thermo Fisher Scientific, 12CA5, 1:2000). Membranes were washed and stained with appropriate IR-conjugated secondary antibodies (anti-mouse antibody, IRDye 800CW Goat anti-mouse IgG secondary [926-32210] and anti-rabbit antibody, IRDye 680CW Goat anti-rabbit secondary antibody [926-68071]) and subsequently imaged using the Li-COR Odyssey imaging system.

Western blot assays. Western blot assays were performed as per ref. 45. Primary antibodies used are as follows: anti-VDAC (Abcam, ab154856, 1:1000) and anti-BiP (MilliporeSigma, G9043, 1:3,000). HRP-conjugated secondary antibodies were used (Southern Biotech, 4010-04, 1:10,000). Immunoblots were developed using ECL prime (GE Healthcare, GERP2232) and imaged using a chemiluminescence detector (Vilber Lourmat). Once imaged, the membrane was stripped by incubating in 1X stripping buffer (200 mM glycine, 0.1% SDS, 1% Tween 20 [MilliporeSigma Aldrich, P9416], pH 2.2) twice for 10 minutes, washed in PBST, and stained with Direct blue (MilliporeSigma Aldrich, 212407) as described previously (46) to detect total protein. The blot images were quantified using Image Lab software (Bio-Rad).
Mitochondrial function. Oxygen consumption rate was measured in zebrafish embryos using the Seahorse Bioscience XF 24 extracellular flux analyzer, as previously described with slight modifications (47). In brief, 3 dpf atrogin-1+/+ or atrogin-1–/– larvae were placed into individual wells of a 24-well XF 24 islet plate (catalog 101122-100) in 630 μL E3 media, in a randomized order. An islet capture screen was added to each well to ensure zebrafish embryos remains in the measurement chamber throughout the assay. A calibrated Seahorse XFe24 Extracellular Flux Assay Kit (catalog 102340-100) was used to measure basal respiration, maximal respiration, spare respiratory capacity, and nonmitochondrial oxygen consumption by titrating FCCP, rotenone, and antimycin A (final concentration of 2 μM for each drug following injection). Each parameter was assessed at least 5 times, and the assay was performed in triplicate. Notably, any larvae that had less than 5% changes in oxygen consumption rates following FCCP and/or rotenone and antimycin A injection were excluded from subsequent analyses.

Untargeted proteomics using nanoLC ESI DIA-MS data and Spectronaut. Samples were lysed in SDS lysis buffer (5% w/v sodium dodecyl sulphate, 100 mM HEPES, pH 8.1), heated at 95°C for 10 minutes and then probe-sonicated before measuring the protein concentration using the BCA method. The lysed samples were denatured and alkylated by adding TCEP (Tris(2-carboxyethyl) phosphine hydrochloride) and CAA (2-Chloroacetamide) to a final concentration of 10 mM and 40 mM, respectively, and the mixture was incubated at 55°C for 15 minutes. Sequencing grade trypsin was added at an enzyme-to-protein ratio of 1:50 and incubated overnight at 37°C after the proteins were trapped using S-Trap mini columns (Profia). Tryptic peptides were sequentially eluted from the columns using (a) 50 mM TEAB, (b) 0.2% formic acid, and (c) 50% acetonitrile, 0.2% formic acid. The fractions were pooled and concentrated in a vacuum concentrator prior to MS analysis.

Using a Dionex UltiMate 3000 RSLCnano system equipped with a Dionex UltiMate 3000 RS autosampler, an Acclaim PepMap RSLC analytical column (75 μm × 50 cm, nanoViper, C18, 2 μm, 100 Å; Thermo Fisher Scientific), and an Acclaim PepMap 100 trap column (100 μm × 2 cm, nanoViper, C18, 5 μm, 100Å; Thermo Fisher Scientific), the tryptic peptides were separated by increasing concentrations of 80% acetonitrile/0.1% formic acid at a flow of 250 nL/min for 158 minutes and analyzed with a QExactive HF mass spectrometer (Thermo Fisher Scientific operated in data-independent acquisition [DIA] mode; 43 sequential DIA windows [resolution width, 14 m/z] were acquired [375–975 m/z; resolution, 15.000; AGC target, 2 × 105; maximum IT, 22 ms; HCD Collision energy, 27%]) following a full MS1 scan (resolution, 60.000; AGC target, 3 × 106; maximum IT, 54 ms; scan range, 375–1,575 m/z). Acquired DIA data were evaluated in Spectronaut 14 (Biognosys) using an in-house spectral library.

Birefringence assays. Skeletal muscle birefringence was examined using an Abrio polarizing microscope as per previously established protocols (48).

Movement assays. The Zebrabox was used to determine the distance and time swum by 6 dpf larvae as per ref. 25. Average speed was calculated by dividing total distance by time.

Drug concentrations. All drug treatments were done on 3 dpf larvae for 3 days, with the drug changed in each day. Rotenone used to inhibit mitochondrial complex 1 was used at 10 nM. HM03, a BiP-specific inhibitor was used at 1 μM.

Statistics. The GraphPad Prism statistics package was used to analyze data in this study. The number of independent biological replicates (number of lays from different parents) examined for each experiment, the number of fish used within each replicate, the significance tests used, and the associated t/F value, degrees of freedom, and exact P values obtained are detailed in Supplemental Tables 1 and 2. Statistical tests included 1-way ANOVA with Tukey’s multiple correction post hoc test, 2-way ANOVA with Šidák’s multiple correction post hoc test, χ² test, unpaired 2-tailed t test, and Fisher’s exact test. P values of less than 0.05 were considered significant.

Study approval. Fish maintenance was carried out as per the standard operating procedures approved by the Monash Animal Ethics Committee under breeding colony licenses ERM14481 and ERM22161. The generation of transgenic and mutant strains was approved by Monash Animal Ethics Committee (approval nos. ERM16963 and ERM22161).

Data availability. The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE (49) partner repository, with the data set identifier PXD038406. All other raw data and files for statistical analysis are available in the Supporting Data Values file and at Figshar (https://figshare.com/s/2885f8fd3167271929c8).
Author contributions
The project was conceptualized by AAR and PDC. Methodology was provided by AAR and MM. Formal analyses were performed by AAR and CH. Investigation was performed by AAR, MM, CH, JM, SFLW, JDH, CS, LBM, AS, RBS, and TEH. The original draft of the manuscript was written by AAR. Reviewing and editing of the manuscript was performed by AAR and PDC. Visualization was provided by AAR. Supervision was performed by AAR, GSL, RBS, and PDC. Project administration was provided by AAR. Funding was acquired by AAR and PDC.

Acknowledgments
We would like to thank Monash Micro Imaging for assistance with microscope maintenance and setup and Monash Fishcore staff for technical assistance. This work was supported by a Medical Research Future Fund grant to PDC, AAR, and GSL (2015993), a National Health and Medical Research Council of Australia fellowship to PDC (GNT 1136567), a Muscular Dystrophy Association (MDA) grant to PDC (MDA 952141), a French Muscular Dystrophy Association (AFM-Télétom) postdoctoral fellowship to AAR (23714), and a Cure CMD grant to AAR and PDC (1018514). The Australian Regenerative Medicine Institute is supported by funds from the state government of Victoria and the Australian federal government. This study used Bioplatforms Australia–enabled/National Collaborative Research Infrastructure Strategy–enabled infrastructure located at the Monash Proteomics and Metabolomics Facility. The graphical abstract was created with BioRender.com.

Address correspondence to: Avnika Ruparelia, Centre for Muscle Research, Level 5W, Medical Building 181, University of Melbourne, Parkville, Victoria 3010, Australia. Phone: 61.3.8344.8786; Email: avnika.ruparelia@unimelb.edu.au. Or to: Peter D. Currie, Australian Regenerative Medicine Institute, Level 1, 15 Innovation Walk, Monash University, Wellington Road, Clayton, Victoria 3800, Australia. Phone: 61.3.99029602; Email: peter.currie@monash.edu.


